ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Drug Delivery

Bluebird and Gritstone team up on oncology cell therapy

by Rick Mullin
August 31, 2018 | APPEARED IN VOLUME 96, ISSUE 35

 

Gene therapy specialist Bluebird Bio and immunotherapy drug development firm Gritstone Oncology have agreed to collaborate on research, development, and commercialization of cell therapy treatments for cancer. Gritstone, based in Emeryville, Calif., will use its artificial intelligence tumor-analysis platform to identify tumor-specific targets and natural T-cell receptors, to which Bluebird will apply its cell therapy approach. Bluebird, based in Cambridge, Mass., will conduct all development, manufacturing, and commercialization activities, while Gritstone will apply its technology to support patient selection for clinical development of therapies.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment